SCHEDULE: RA Capital Management Discloses 6.3% Stake in Avalo Therapeutics

RA Capital Management, along with affiliated entities and individuals, has reported beneficial ownership of 3,483,099 shares, representing 6.3% of Avalo Therapeutics, Inc.'s common stock.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. have collectively disclosed beneficial ownership of 3,483,099 shares of Avalo Therapeutics, Inc. common stock.
• This holding represents 6.3% of the company's outstanding common stock as of June 30, 2026.
• The filing indicates that RA Capital Management serves as the investment adviser for the Fund and may be deemed a beneficial owner of the securities held by the Fund.
• The Fund directly holds 1,000,000 shares and Series C preferred stock convertible into an additional 2,483,099 shares of common stock.
• Voting and dispositive power for the Fund's securities have been delegated to RA Capital Management.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but not controlling stake in Avalo Therapeutics, Inc. by RA Capital Management and its affiliates.

Positives

• Significant investment by a known healthcare-focused investment firm (RA Capital Management) indicates confidence in Avalo Therapeutics' potential.
• The disclosure confirms a substantial shareholding, which could lead to increased liquidity and market interest in the stock.
• The convertible preferred stock provides a pathway for further potential equity dilution, which can be a positive for the company's capital structure if used strategically.

Negatives

• The filing does not provide specific details on the investment strategy or the rationale behind acquiring this stake.
• The delegation of voting and dispositive power to RA Capital Management means that the Fund itself disclaims beneficial ownership, which could be a point of confusion for some investors.
• The potential for conversion of preferred stock into common stock represents future dilution for existing shareholders.

Risks

• Future conversion of preferred stock could dilute existing shareholders' ownership percentage.
• The investment firm's strategy could involve active engagement or potential future changes in its stake, which could impact stock price volatility.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from Avalo Therapeutics. However, the investment by RA Capital Management may signal a positive outlook from the investment firm regarding the company's future prospects.

Management Comments

• RA Capital Management serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Fund.
• The Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days' notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act.
• As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital.
• RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G/A other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G/A shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

Industry Context

StockSavvy.ai notes that RA Capital Management is a prominent investment firm known for its significant involvement in the biotechnology and healthcare sectors. Their investment in Avalo Therapeutics suggests a belief in the company's technology or pipeline, aligning with broader trends of venture capital and institutional investment in innovative biotech companies.

Comparison to Industry Standards

• RA Capital Management's typical investment size in early-stage or development-stage biopharmaceutical companies can range from single-digit to double-digit percentages of a company's outstanding shares, depending on the stage and perceived potential.
• A 6.3% stake is a substantial position, often indicative of a significant conviction, and places RA Capital among the larger institutional holders.
• Other institutional investors in the biotech space often take similar positions, especially in companies with promising but unproven drug candidates or technologies.

Stakeholder Impact

• Shareholders: Potential for increased market interest and liquidity due to a significant institutional investor. Future dilution risk exists from preferred stock conversion.
• Company Management: May benefit from the strategic input or increased scrutiny from a large, active investor like RA Capital.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Monitor Avalo Therapeutics' progress and any future announcements from RA Capital Management regarding their stake or involvement.
• Observe potential conversion of preferred stock into common stock and its impact on share count.

Key Dates

Recommendation

The filing indicates a significant investment by a reputable firm, which is a positive signal. However, it is a disclosure of ownership and not an endorsement or a report on company performance. The potential for future dilution from convertible preferred stock warrants a cautious 'hold' stance until further performance data or strategic updates from Avalo Therapeutics are available.

Keywords

Avalo Therapeutics, RA Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Preferred Stock, Investment Adviser, Healthcare Fund